Slide 1: VAX-31 Phase 1/2 Study Topline Results in Adults Aged 50 and Older
VAX-31 Phase 1/2 Study Topline Results in Adults Aged 50 and Older September 3, 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements
September 3, 2024 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s vaccine candidate
Slide 3: Vaxcyte Mission Statement
September 3, 2024 VAXCYTE MISSION STATEMENT We are on a global mission to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases.
Slide 4: Agenda
September 3, 2024 Agenda Introduction and vax-31 Results Overview VAX-31 Phase 1/2 Study TOPLINE results in Adults Aged 50 and Older Disposition and Demographics Tolerability and Full Six-Month Safety Data Topline Immunogenicity Data PCV franchise status and Next Steps
Slide 5: Introduction and VAX-31 Results Overview
Introduction and VAX-31 Results Overview September 3, 2024
Slide 6: Unprecedented Results Support Potential Best-in-Class PCV With Broadest Serotype and Disease Coverage
Unprecedented Results Support Potential Best-in-Class PCV With Broadest Serotype and Disease Coverage Summary of VAX-31 Adult 50+ Phase 1/2 Study Topline Data Findings September 3, 2024 SAFETY AND TOLERABILITY: At all doses studied, VAX-31 was well tolerated and demonstrated a safety profile similar
Slide 7: Global Health Impact of Pneumococcal Disease Remains Significant
September 3, 2024 Over 150,000 U.S. hospitalizations annually due to pneumococcal pneumonia Streptococcus pneumoniae is the leading cause of vaccine preventable deaths globally in children under five ~300,000 children under five years old die annually worldwide due to Streptococcus pneumoniae Global
Slide 8: VAX-31 Phase 1/2 Study Topline Results in Adults Aged 50 and Older
VAX-31 Phase 1/2 Study Topline Results in Adults Aged 50 and Older September 3, 2024
Slide 9: VAX-31 Phase 1/2 Clinical Study Design (N=1,015)
Randomized, Observer-Blind, Dose-Finding, Controlled Study to Evaluate Safety, Tolerability and Immunogenicity of VAX-31 vs Standard-of-Care (PCV20) in 1,015 Healthy Adults ≥ 50 Years Dose Blood Sample PCV20 VAX-31 High Dose VAX-31 Middle Dose VAX-31 Low Dose Safety Follow-Up Randomize (1:1:1:1) Scr
Slide 10: Study Evaluated Three VAX-31 Doses
Study Evaluated Three VAX-31 Doses September 3, 2024 Low Dose (1.1mcg) High Dose (3.3mcg) PCV20 VAX-31 (2.2mcg) 1 3 4 5 6A 6B 7F 8 9V 10A 11A 12F 14 15B 18C 19A 19F 22F 23F 33F 2 9N 17F 20 7C 15A 16F 23A 23B 31 35B 1.65 mcg 1.65 mcg 1.65 mcg 3.3 mcg 3.3 mcg 3.3 mcg 4.4 mcg 4.4 mcg 4.4 mcg 4.4 mcg Mi
Slide 11: Study Safety, Tolerability and Immunogenicity Key Outcome Measures
Study Safety, Tolerability and Immunogenicity Key Outcome Measures September 3, 2024 Safety and Tolerability Outcome Measures Immunogenicity Outcome Measures DAY 8 MONTH 1 MONTH 6 Solicited local reactions Solicited systemic events Unsolicited adverse events (AE) Laboratory parameters Serious advers
Slide 12: Disposition and Demographics
Disposition and Demographics September 3, 2024
Slide 13: Study Disposition
Study Disposition High Proportion of Subjects with Safety and Immunogenicity Follow-Up September 3, 2024 Phase 1/2 Study in Adults 50+ 24 subjects (2.4%) discontinued and did not complete the full Month 6 safety follow-up (lost to follow-up (13), withdrawal by subject (11)). Enrolled N = 1,015 Inclu
Slide 14: Population Demographics Generally Balanced Across Cohorts
Population Demographics Generally Balanced Across Cohorts and Similar for the Safety and Immunogenicity Populations September 3, 2024 VAX-31 Low Dose VAX-31 Middle Dose VAX-31 High Dose PCV20 Safety Immunogenicity Safety Immunogenicity Safety Immunogenicity Safety Immunogenicity Number of Subjects 2
Slide 15: Tolerability and Full Six-Month Safety Data
Tolerability and Full Six-Month Safety Data September 3, 2024
Slide 16: Local Solicited AEs Through Day 7
September 3, 2024 Local Solicited AEs Through 7 Days All VAX-31 Doses Well Tolerated and Consistent with PCV20 Across Cohorts % of Subjects
Slide 17: Systemic Solicited AEs Through Day 7
September 3, 2024 . Systemic Solicited AEs Through 7 Days All VAX-31 Doses Well Tolerated and Consistent with PCV20 Across Cohorts % of Subjects
Slide 18: VAX-31 Full Six-Month Safety Data Similar to PCV20 and Across Cohorts
VAX-31 Full Six-Month Safety Data Similar to PCV20 and Across Cohorts September 3, 2024 VAX-31 Low Dose VAX-31 Middle Dose VAX-31 High Dose PCV20 Number of Subjects with: 255 254 253 253 Unsolicited TEAE, n (%) 42 (16.5) 43 (16.9) 47 (18.6) 42 (16.6) Related Unsolicited TEAE, n (%) 7 (2.7) 11 (4.3)
Slide 19: Topline Immunogenicity Data
Topline Immunogenicity Data September 3, 2024
Slide 20: Precedent Immunogenicity Regulatory Criteria for Phase 2/3 PCV Studies
Criteria for 11 Incremental Serotypes in VAX-31: Criteria for 20 Serotypes Common to VAX-31 and PCV20: Precedent Immunogenicity Regulatory Criteria for Phase 2/3 PCV Studies September 3, 2024 CI = confidence interval . Non-inferiority: Lower bound of the 2-sided 95% CI of the OPA GMR is greater than
Slide 21: Middle and High Doses Met OPA Non-Inferiority Criteria for All 20 Common STs
September 3, 2024 Middle and High Doses Met OPA Response Non-Inferiority Criteria for All 20 Common STs Compared to PCV20 VAX-31 Induced Robust Immune Responses for All 20 Common STs GMR: * * * * * * * * * * * * * Reached statistical significance for superiority. Low dose: 8 of 20 STs had a GMR grea
Slide 22: VAX-31 Induced Robust Immune Responses for All Incremental STs
VAX-31 Induced Robust Immune Responses for All 11 Incremental STs All Three Doses Met Superiority Criteria for All Incremental STs Compared to PCV20 September 3, 2024 % difference with a > 4-fold OPA titer increase (95% CI) GMR:
Slide 23: Consistent Dose-Dependent Response for Common STs
Topline Data Affirm Potential Predictability and Scalability of Site-Specific, Carrier-Sparing Approach September 3, 2024 Consistent Dose-Dependent Response for Common STs VAX-31 Low Dose VAX-31 Middle Dose VAX-31 High Dose GMR:
Slide 24: Consistent Dose-Dependent Response for Incremental STs
September 3, 2024 Topline Data Affirm Potential Predictability and Scalability of Site-Specific, Carrier-Sparing Approach Consistent Dose-Dependent Response for Incremental STs GMR:
Slide 25: IgG Data Consistent with OPA Results
IgG Data Consistent with OPA Results All 31 Serotypes in VAX-31 Demonstrated Robust IgG GMC Responses September 3, 2024 Non-PCV20 Serotypes Serotypes Contained in PCV20 IgG = Immunoglobulin G; GMC = Geometric Mean Concentration
Slide 26: PCV Franchise Status and Next Steps
PCV Franchise Status and Next Steps September 3, 2024
Slide 27: Potential to Set New Standard-of-Care with Broadest Coverage
Potential to Set New Standard-of-Care with Broadest Coverage and Raise Immunogenicity Threshold September 3, 2024 SAFETY AND TOLERABILITY: At all doses studied, VAX-31 was well tolerated and demonstrated a safety profile similar to PCV20 IMMUNOGENICITY: At all doses studied, VAX-31 demonstrated robu
Slide 28: Potential Best-in-Class PCV Franchise for Adult and Infant Segments
Potential Best-in-Class PCV Franchise for Adult and Infant Segments September 3, 2024 24-valent PCV candidate VAX-24 Infants Announce topline safety, tolerability and immunogenicity data from primary three-dose immunization series of Phase 2 study, which is fully enrolled with 802 healthy infants, b
Slide 29: VAX-31 Poised to Establish New Standard for Spectrum of Coverage
VAX-31 Poised to Establish New Standard for Spectrum of Coverage 4 6B 9V 14 18C 19F 23F 1 5 7F 3 6A 19A 22F 33F 8 10A 11A 12F 15B/C 2 9N 17F 20 7C 15A 16F 23A 23B 31 35B 24F Source: Prescribing information for Prevnar, Prevnar 13, Prevnar20, Vaxneuvance, Prevnar 20 and Capvaxive. Company filings for
Slide 30: VAX-31 Positioned to Potentially Provide Unrivaled IPD Coverage
PCV20: 55.3% coverage PCV21: 83.6% coverage VAX-31: 95.6% coverage September 3, 2024 ESTIMATED COVERAGE OF PCVs BASED ON CIRCULATING IPD SEROTYPES1 VAX-31 Positioned to Potentially Provide Unrivaled IPD Coverage % US coverage is the percentage of IPD caused in individuals >50yrs of age in the United
Slide 31: Pneumococcal Vaccine Market Poised for Significant Growth
September 3, 2024 ~$13B ~$8B Pfizer (Prevnar Family – PCV13 & PCV20) Merck (PPSV23 & PCV15) GSK (Synflorix) Billions Other Sources: Company websites. Global Pneumococcal Vaccine Market (2022-2027), Infogence Global Research. Shea KM, Edelsberg J, Weycker D et al. (2014), Open Forum Infect Dis 1(1):
Slide 32: Vaxcyte Mission Statement
September 3, 2024 VAXCYTE MISSION STATEMENT We are on a global mission to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases.
Slide 33: Q&A with Management
September 3, 2024 Q&A with Management Grant Pickering Chief Executive Officer, Director and Founder Jim Wassil Executive Vice President and Chief Operating Officer Andrew Guggenhime President and Chief Financial Officer
Slide 34: Vaxcyte
VAXCYTE pritecl humanbind